Antimicrobial agents

Patent metadata

Field	Value
Publication number	US-11052137-B2
Application number	US-201816169472-A
Country	US
Kind code	B2
Filing date	Oct 24, 2018
Priority date	Jun 26, 2009
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

First claim

The invention claimed is:

1. A fusion protein comprising an endolysin having the activity of degrading the cell wall of Gram-negative bacteria and a peptide segment fused to the endolysin at the N- or C-terminus or at both termini, wherein the peptide segment is a cathelicidine or a magainine.

2. The fusion protein according to claim 1 , wherein the peptide segment consists of about 12 to about 100 amino acid residues.

3. The fusion protein according to claim 2 , wherein the peptide segment consists of about 12 to 50 amino acid residues.

4. The fusion protein according to claim 2 , wherein the peptide segment consists of about 12 to 30 amino acid residues.

5. The fusion protein according to claim 1 , wherein said fusion protein comprises an additional amino acid residue on the N-terminus.

6. The fusion protein according to claim 1 , wherein said fusion protein comprises a tag or additional protein on the C- and/or N-terminus.

7. The fusion protein according to claim 1 , wherein the peptide segment is linked to the endolysin by one or more additional amino acid residues.

8. The fusion protein according to claim 1 , wherein the endolysin comprises an amino acid sequence according to any of SEQ ID NO: 1, 2, 3, 4, 5, 18, 20, 21, 22, 23, 24, 25 or 34.

9. The fusion protein according to claim 1 , wherein the peptide segment comprises an amino acid sequence according to any of SEQ ID NO: 9, 10, 11, 12, or 13.

10. The fusion protein according to claim 1 , wherein the Gram-negative bacteria are selected from the group consisting of:
Enterobacteriaceae, Pseudomonadaceae, Neisseria, Moraxella, Vibrio, Aeromonas, Brucella, Francisella, Bordetella, Legionella, Bartonella, Coxiella, Haemophilus, Pasteurella, Mannheimia, Actinobacillus, Gardnerella , Spirochaetaceae, Leptospiraceae, Campylobacter, Helicobacter, Spirillum, Streptobacillus , Bacteroidaceae and Acinetobacter.

11. The fusion protein according to claim 10 , wherein the Gram-negative bacteria are selected from the group consisting of Escherichia, Salmonella, Shingella, Citrobacter, Edwardsiella, Enterobacter, Hafnia, Klebsiella, Moganella, Proteus, Providencia, Serratia, Yersinia, Pseudomonas, Burkholderia, Stenotrophomonas, Shewanella, Sphingomonas, Comamonas, Treponema, Borrelia, Bacteroides, Fusobacterium, Prevotella, Porphyromonas and A. baumanii.

12. An isolated nucleic acid molecule encoding a fusion protein according to claim 1 .

13. A vector comprising the nucleic acid molecule according to claim 12 .

14. A host cell comprising the nucleic acid molecule according to claim 12 or the vector according to claim 13 .

15. The host cell according to claim 14 , wherein the cell is a bacterial cell or a yeast cell.

16. A pharmaceutical composition comprising a fusion protein according to claim 1 .

17. A fusion protein comprising an endolysin having the activity of degrading the cell wall of Gram-negative bacteria and a peptide segment fused to the endolysin at the N- or C-terminus or at both termini, wherein the peptide segment comprises SEQ ID NO: 33.

Assignees

• Lysando Ag
• Univ Leuven Kath

Inventors

• Lavigne Rob
• Miller Stefan
• Briers Yves
• Volckaert Guido
• Walmagh Maarten

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61K38/46

  Hydrolases (3) · CPC title

• C12N9/2462

  Lysozyme (3.2.1.17) · CPC title

• A61K38/47 Primary

  acting on glycosyl compounds (3.2), e.g. cellulases, lactases · CPC title